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The myelodysplastic syndromes (MDS) represent a compen-
dious group of clonal hematopoietic disorders characterized by
ineffective hematopoiesis resulting in peripheral blood cytopenias
and a signiﬁcant risk of transformation to acute myeloid leukemia
(AML). The degree of cytopenia, blast percentage, and presentation
karyotype permit identiﬁcation of patients with high-risk MDS
whose outcome is particularly poor. Targeted mutational analysis
has transformed our understanding of the pathogenesis of MDS
and, at the same time, provided the tools for preliminary analyses
of clonal structure. Acquired abnormalities in classes of genes de-
termining chromatin structure, including mutations in DNMT3A,
TET2, IDH1, and IDH2 (which inﬂuence CpG island methylation
status) and EZH2 and ASZL1 (which contribute to the control of
histone acetylation) are commonly observed in MDS and likely
contribute to disease pathogenesis.1
Currently, the only curative treatment in MDS is alloge-
neic stem-cell transplantation. Over the last decade, pharma-
cologic reversal of acquired abnormalities in chromatin structure
has emerged as a plausible therapeutic strategy in a range of he-
matologic malignancies, notably AML and MDS, where inhibitors
of DNA methyltransferase (DNMT) and histone deacetylase en-
zymes have demonstrated activity in preclinical models.2 Indeed,
the most important therapeutic advance in the treatment of adult
higher-risk MDS, particularly in older patients ineligible for
intensive chemotherapy or allogeneic stem-cell transplantation,
has been the demonstration that the DNMT inhibitors azacitidine
(AZA) and decitabine can produce either complete remission (CR)
or a hematologic improvement in a signiﬁcant number of patients.3,4
Furthermore, in a prospective randomized trial, AZA was shown to
improve overall survival (OS), thereby representing the ﬁrst phar-
macologic agent to alter the natural history of high-risk MDS.5
Importantly, recent prospective trials have also demonstrated im-
proved OS after AZA therapy in older adults with AMLwho are not
eligible for intensive chemotherapy.6 The current subcutaneous
mode of administration of AZA is inconvenient and sometimes
painful, but the recent development of a relatively well-tolerated
formulation, CC486, with augmented pharmacokinetics promises
to transform the ease of administration of an agent that has now
become the standard of care in older patients with high-risk MDS.7
Of interest, CC486 also demonstrates clinical activity in patients
who have experienced treatment failure with subcutaneous AZA,
suggesting that the more prolonged exposure to AZA delivered by
CC486 can result in clinical responses in patients resistant to AZA.
It remains the case, however, that only a minority of patients
treated with AZA achieve a bone marrow CR or CRi (characterized
by a reduction in bone marrow blast percentage to , 5% without
complete peripheral count recovery), and disease progression
remains inevitable. Consequently, the last decade has witnessed an
active search for novel agents with the capacity to both improve
response rates and prolong survival in AZA-treated patients. In
preclinical models, the combination of AZA with histone deace-
tylase inhibitors, such as sodium valproate, etinostat, and vor-
inostat, markedly increases antitumor activity.2 Indeed, two early-
phase studies of combined AZA and vorinostat administration
seemed encouraging, with CR rates reported between 50% and
70%.8,9 An alternative strategy that has shown promising results in
early-phase trials is combination with the immunomodulatory
drug lenalidomide.10 Consequently, the prospective randomized
trial by Sekeres et al11 reported in the article that accompanies this
editorial, which demonstrated no increase in either overall re-
sponse rate or survival in patients with high-risk MDS treated with
either combination compared with AZA monotherapy, is im-
portant and consistent with recent studies showing no beneﬁt of
combining AZAwith entinostat or pracinostat.12,13 Why might this
meticulously conducted trial have failed to replicate the encour-
aging results of previous early-phase trials using both drug
combinations? Such disparities are most commonly attributed to
potential selection bias in early-phase trials, and it is therefore
important to note that in this study, the demographic and mo-
lecular characteristics of the trial population appear representative
of a typical population of patients with high-risk MDS. Alterna-
tively, it is possible that the additional toxicity observed with the
experimental combination arms resulted in either underdosing of
AZA or premature cessation of combination therapy, and this
possibility is supported by the trend toward improved survival in
the vorinostat arm despite increased toxicity.
On the assumption that therapeutic decision making should
be informed by Einstein’s apocryphal observation that the deﬁ-
nition of insanity is doing the same thing over and over again and
expecting different results, it is perhaps important now to consider
what alternative strategies might improve the clinical activity of
AZA with regard to both increasing CR rate and prolonging OS.
Rational construction of novel AZA-based combinations is ham-
pered by our failure to fully understand both how AZA exerts its
antitumor effect and the cellular basis of disease relapse in this
clinical setting. Studies correlating upregulation of key cell cycle
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regulators, such as CDKN1A, with AZA’s activity in both in vitro
and animal models of AML implicate induction of G1/S cell cycle
arrest as one of the mechanisms of AZA-induced antitumor ac-
tivity. These observations provide a rationale for combining AZA
with inhibitors that target G2 checkpoint kinases, such as Wee1,
Chk1, or ATR. Combination with other agents that exert a p53-
independent mechanism of killing is also of interest, and it is
noteworthy that in preliminary studies, coadministration of AZA
with the Bcl-2 inhibitor venetoclax has been reported to produce
CR rates of up to 70% in newly diagnosed patients with high-risk
MDS and AML.14
The major cause of treatment failure in AZA-treated patients
is the almost-universal occurrence of disease resistance; con-
sequently, strategies with the capacity to maintain bone marrow
responses are required. The occurrence at relapse of subclones
present at only a low frequency at diagnosis in AZA-treated pa-
tients supports the implementation of a sequential therapeutic
strategy using targeted agents such as FLT3ITD, IDH1, or IDH2
inhibitors in combination with AZA,15 potentially on the basis of
sequential analysis of clonal structure. At the same time, immu-
nophenotypic characterization of the stem/progenitor cell com-
partments containing leukemic stem cells permits serial quantitation
of leukemic stem/progenitors during therapy.16 A current but largely
untested hypothesis is that this population serves as a reservoir of
disease resistance, which, if conﬁrmed, raises the possibility of both
using serial quantitation of this population as a biomarker of re-
sponse to novel AZA-based combinations and highlights the im-
portance of developing novel drug or antibody treatment strategies
with the potential to target residual leukemic stem/progenitor cells.
A major factor limiting the effective use of AZA in clinical
practice is the challenge of identifying the patients likely to obtain
a major clinical beneﬁt at the start of treatment, either in terms
of CR acquisition or improved survival. A notable feature of the
article by Sekeres et al11 is the prospective correlation of clinical
response with the results of next-generation sequencing of
40 candidate myeloid genes. In previous retrospective analyses,
mutations in DNMT3A have been shown to correlate with an
increased likelihood of achieving a clinical response to AZA, al-
though this has not been consistently observed.17 It is therefore of
considerable interest that this observation was replicated in this
prospective study because just as retrospective phase I/II trials can
yield unreproducible clinical observations, the samemay also apply
to the previous, mostly retrospective, analyses of the molecular
predictors of response to AZA-based therapy. Just as importantly,
this prospective evaluation provides a template for integrating
mutational proﬁling into future trials of AZA-based combination
therapy.
More generally, the increasing molecular stratiﬁcation of dis-
eases previously considered homogeneous clinical entities, such
as MDS and AML, coupled with the tsunami of emergent novel
therapies, poses profound questions about the scale and capacity
of the translational infrastructure that will be required if we are to
rapidly assess an exponentially increasing number of promising
novel drug, antibody, and cellular therapies in ever-decreasing
genetically deﬁned disease populations. What is increasingly clear
is that our current reliance on both trial designs and translational
infrastructures that may have been ﬁt for purpose in 2007 when
the therapeutic cupboard was bare threatens to disadvantage
patients, academia, and the pharmaceutical sector in the next
decade. Although the precise models that will be required to
realize the therapeutic promise of the next decade will be nuanced
according to factors such as disease incidence, molecular strat-
iﬁcation, and therapeutic opportunities, certain common prin-
ciples can be predicted to apply. At the heart of accelerated trial
delivery is the establishment of resourced trial networks with a suf-
ﬁcient density of patients to allow the rapid assessment of a range of
novel therapies as developed so effectively in stem-cell transplantation
and planned for antibiotic trials.18,19 Such networks should be ap-
propriately resourced and incentivised to reward rapid trial devel-
opment with enhanced pharmacovigilance allowing trial delivery
to regulatory standard, removing the current inefﬁcient split be-
tween commercial and academic studies. Finally, integration of next-
generation sequencing, studies of measurable residual disease and
candidate biomarkers, where possible in real time, must be ensured so
that both discovery science and trial delivery have the opportunity to
impact clinical care as swiftly as possible.
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